Stay updated with breaking news from Bryan Stuart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fulcrum TherapeuticsAnnounces Second Quarter 2022 Financial Results and Business Update - Presented initial data from Phase 1b trial in sickle cell disease ,... | August 11, 2022
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint
Fulcrum Therapeutics, Inc. (NASDAQ:NASDAQ:FULC) Q1 2022 Earnings Conference Call May 9, 2022, 8:00 am ET Company Participants Naomi Aoki - SVP, Corporate Communications & IR Bryan...
03.03.2022 - – Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 – – On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease in 2Q 2022 – – Conference call scheduled for ...
Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be... | December 6, 2021